25 June 2024

Mosunetuzumab (subcutaneous injection) for treating relapsed or refractory follicular lymphoma

Mosunetuzumab is in clinical development for the treatment of relapsed or refractory follicular lymphoma (FL). FL is a type of blood cancer originating in the lymph nodes of the immune system, and it is the most common type of low-grade Non-Hodgkin’s Lymphoma in the UK. A relapsed or refractory cancer is one that has come back after a successful treatment regimen or has not responded to a previous regimen, meaning a new interventional approach is required in both cases. Although the survival rates for FL are relatively high compared to some other cancers, the disease can cause a range of issues that decrease patient quality of life. There are currently limited options for the second-line or greater treatments required for relapsed and refractory patients with FL. This indicates that there remains an unmet need to treat relapsed or refectory FL.